Showing 4951-4960 of 10821 results for "".
- Revance Therapeutics Initiates Phase 3 Clinical Trial of Botulinum Toxin Type A Topical Gel for Crow's Feethttps://practicaldermatology.com/news/revance-therapeutics-initiates-phase-3-clinical-trial-of-botulinum-toxin-type-a-topical-gel-for-crows-feet/2458857/Revance Therapeutics, Inc. has commenced dosing patients in the Phase 3 pivotal study to evaluate the safety and efficacy of its RT001 investigational topical drug product candidate for the treatment of lateral canthal lines, or crow’s feet. The Phase 3 trial will evaluate the safety and ef
- Solta Medical Launches Clear + Brilliant pelo for Laser Hair Removalhttps://practicaldermatology.com/news/solta-medical-launches-clear-brilliant-pelo-for-laser-hair-removal/2458875/Solta Medical, a division of Valeant Pharmaceuticals North America LLC launched its Clear + Brilliant pelo™ laser for permanent hair reduction. The US launch of this device, which joins Solta Medical's aesthetic device portfolio, follows a unique partnership with German Medical
- FDA Approves Updated Label for Allergan's Teflaro for Treatment of ABSSSIhttps://practicaldermatology.com/news/fda-approves-updated-label-for-allergans-teflaro-for-treatment-of-absssi/2458880/The FDA approved Allergan’s supplemental new drug application (sNDA) to update the label for Teflaro® (ceftaroline fosamil) for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP).
- Miramar Labs to Launch miraSmooth Treatment with FDA Clearance of miraDry For Permanent Reduction of Underarm Hairhttps://practicaldermatology.com/news/miramar-labs-to-launch-mirasmooth-treatment-with-fda-clearance-of-miradry-for-permanent-reduction-of-underarm-hair/2458906/Miramar Labs’ miraDry® System received FDA clearance for the treatment of unwanted underarm hair, and permanent reduction of underarm hair of all colors. Miramar Lab's proprietary miraWave® technology—use of precisely controlled microwave energy—is the founda
- R. Scott Peterson Is New Head of Medical Affairs at SkinCeuticalshttps://practicaldermatology.com/news/r-scott-peterson-is-new-head-of-medical-affairs-at-skinceuticals/2458946/R. Scott Peterson, PhD has been named Head of Medical Affairs at SkinCeuticals. In his new role at SkinCeuticals, Dr. Peterson will lead the medical affairs team and expand regional scientific services to support the realization of the company's miss
- American Academy of Dermatology Donates Shade Structure to the Smithsonian's National Zoohttps://practicaldermatology.com/news/american-academy-of-dermatology-donates-shade-structure-to-the-smithsonians-national-zoo/2458948/The American Trail Amphitheatre at the Smithsonian’s National Zoo now has built-in sun protection, thanks to a shade structure donation from the American Academy of Dermatology (AAD). The shade structure, which shades the 250-person seating area at the seal and sea lion exhibit, will protec
- Foamix Pharmaceuticals Ltd. Closes Its $69 Million Public Offering of Ordinary Shareshttps://practicaldermatology.com/news/foamix-pharmaceuticals-ltd-closes-its-69-million-public-offering-of-ordinary-shares/2458956/Foamix Pharmaceuticals Ltd. closed its follow-on public offering. A total of 7,419,353 ordinary shares were sold at a price to the public of $9.30 per share. Prior to closing, the underwriters fully exercised their option to purchase 967,741 additional ordinary shares. The net proceeds from the s
- Provectus Biopharmaceuticals' Data on PV-10 to Be Presented at HemOnc Todayhttps://practicaldermatology.com/news/provectus-biopharmaceuticals-data-on-pv-10-to-be-presented-at-hemonc-today/2458972/Provectus Biopharmaceuticals, Inc., a clinical-stage oncology and dermatology biopharmaceutical company ("Provectus"), announced that Dr. Sanjiv Agarwala will present data on PV-10, the Company's novel investigational drug for cancer, at the HemOnc Today Melanoma and Cutaneous
- NuGene BioPharma, Inc. Acquires SkinGuardian®https://practicaldermatology.com/news/nugene-biopharma-inc-acquires-skinguardian/2458986/NuGene International, Inc.’s subsidiary corporation, NuGene BioPharma, Inc., has acquired all rights, title and interest in and to SkinGuardian®, an FDA-approved (monographed) skin protectant, antiseptic, and moisturizing topical cream. NuGene BioPharma acquired all intellectual
- Pfizer Announces FDA Acceptance For Review of Supplemental New Drug Application for Oral Xeljanz For Plaque Psoriasishttps://practicaldermatology.com/news/pfizer-announces-fda-acceptance-for-review-of-supplemental-new-drug-application-for-oral-xeljanz-for-plaque-psoriasis/2459011/The FDA accepted for review Pfizer Inc.’s supplemental New Drug Application (sNDA) for Xeljanz (tofacitinib citrate) 5mg and 10mg tablets, a Janus kinase (JAK) inhibitor, the first in a new class of oral medicines being investigated for the treatment of adult patients with moderate to sever